Further research will be needed to evaluate the advantages of PSMA-PET/CT in challenging situations (e.g., prostatitis, benign prostate hyperplasia or after repeated negative biopsies) or if patients truly benefit from the handling of PSMA-positive findings as dominant intra-prostatic lesions during radiation therapy. Here, FOLH1 is linked to male reproductive organ cancer.